Copyright Reports & Markets. All rights reserved.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption 2014-2024
        • 2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption CAGR by Region
      • 2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
        • 2.2.1 Lynparza
        • 2.2.2 Zejula
        • 2.2.3 Rubraca
        • 2.2.4 Talzenna
        • 2.2.5 Other
      • 2.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
        • 2.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Type (2014-2019)
      • 2.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
        • 2.4.1 Ovarian Cancer
        • 2.4.2 Breast Cancer
        • 2.4.3 Other
      • 2.5 PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
        • 2.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value and Market Share by Application (2014-2019)
        • 2.5.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Application (2014-2019)

      3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers

      • 3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers
        • 3.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2017-2019)
        • 3.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers (2017-2019)
      • 3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers
        • 3.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2017-2019)
        • 3.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2017-2019)
      • 3.3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sale Price by Manufacturers
      • 3.4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
        • 3.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution and Sales Area by Manufacturers
        • 3.4.2 Players PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Regions

      • 4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor by Regions
        • 4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Regions
        • 4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Regions
      • 4.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
      • 4.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
      • 4.4 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth
      • 4.5 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Growth

      5 Americas

      • 5.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries
        • 5.1.1 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
        • 5.1.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
      • 5.2 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
      • 5.3 Americas PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries
        • 6.1.1 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
        • 6.1.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
      • 6.2 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
      • 6.3 APAC PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
        • 7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
        • 7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
      • 7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
      • 7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
        • 8.1.1 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Value by Countries (2014-2019)
      • 8.2 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Type
      • 8.3 Middle East & Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
      • 10.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customer

      11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast

      • 11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Consumption Forecast (2019-2024)
      • 11.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Regions
        • 11.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Regions (2019-2024)
        • 11.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Type
      • 11.8 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast by Application

      12 Key Players Analysis

      • 12.1 AstraZeneca
        • 12.1.1 Company Details
        • 12.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
        • 12.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 AstraZeneca News
      • 12.2 Tesaro
        • 12.2.1 Company Details
        • 12.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
        • 12.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Tesaro News
      • 12.3 Merck & Co
        • 12.3.1 Company Details
        • 12.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
        • 12.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Merck & Co News
      • 12.4 Clovis Oncology
        • 12.4.1 Company Details
        • 12.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
        • 12.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Clovis Oncology News
      • 12.5 Pfizer
        • 12.5.1 Company Details
        • 12.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Offered
        • 12.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Pfizer News

      ...

        13 Research Findings and Conclusion

        PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

        They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

        PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
        The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.

        According to this study, over the next five years the PARP (Poly ADP-Ribose Polymerase) Inhibitor market will register a 34.0% CAGR in terms of revenue, the global market size will reach US$ 5097.7 million by 2024, from US$ 1178.8 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in PARP (Poly ADP-Ribose Polymerase) Inhibitor business, shared in Chapter 3.

        This report presents a comprehensive overview, market shares, and growth opportunities of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by product type, application, key manufacturers and key regions and countries.

        This study considers the PARP (Poly ADP-Ribose Polymerase) Inhibitor value and volume generated from the sales of the following segments:

        Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
        Lynparza
        Zejula
        Rubraca
        Talzenna
        Other
        Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
        Ovarian Cancer
        Breast Cancer
        Other

        This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
        Americas
        United States
        Canada
        Mexico
        Brazil
        APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

        The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
        AstraZeneca
        Tesaro
        Merck & Co
        Clovis Oncology
        Pfizer
        ...

        In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

        Research objectives
        To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
        To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.
        Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
        To analyze the PARP (Poly ADP-Ribose Polymerase) Inhibitor with respect to individual growth trends, future prospects, and their contribution to the total market.
        To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
        To project the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions (along with their respective key countries).
        To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
        To strategically profile the key players and comprehensively analyze their growth strategies.

        Buy now